Declaration of interests AL declares being a member of advisory boards, consultant, or presenter for AstraZeneca, Merck Sharp & Dohme, GlaxoSmithKline, Apmonia, Ability Pharma, Brenus Pharma, Owkin, Blueprint, Seagen, and Zentalis; received research funding (paid to institution) from AstraZeneca, Merck Sharp & Dohme, Pfizer, Roche, GlaxoSmithKline, Incyte, Seagen, Mersana, OseImmuno, and Zentalis; and receiving travel support for attending congresses from AstraZeneca, OseImmuno, and GlaxoSmithKline. BB declares industry sponsored research at Gustave Roussy Cancer Center with AbbVie, Amgen, AstraZeneca, Chugai Pharmaceutical, Daiichi-Sankyo, Ellipse Pharma, Eisai, Genmab, Genzyme Corporation, Hedera Dx, Inivata, Ipsen, Janssen, Merck Sharp & Dohme, PharmaMar, Roche, Genentech, Sanofi, Socar Research, Tahio Oncology, and Turning Point Therapeutics. FA received research funding (compensated to the Gustave Roussy Cancer Center) from Roche, AstraZeneca, Lilly, Pfizer, Novartis, N-power Medicine, Guardant Health, Gilead, Servier, and Boston Pharmaceuticals; and was on the advisory board of Galapagos.